Therapeutic for pancreatic cancer

In most pancreatic cancer patients, the diagnosis occurs when the disease is already advanced, and currently, there is no effective treatment. A group of researchers from the Spanish National Cancer Research Centre (CNIO) may have found a new therapeutic approach.

One of the characteristics of pancreatic cancer is that the tumour cells are embedded in the stroma, which represents 90 percent of the tumour mass and which seems to form a barrier (physical and chemical) hindering treatment with inhibitors, chemotherapy and immunotherapy.

Researchers focused their work on identifying a stromal cell population that fosters tumour growth, to later discover why they have this capacity and reverse it. The strategy to achieve the latter is innovative, because instead of eliminating these stromal cells which help the tumour, the objective has been their selective reprogramming. The researchers focused on a subpopulation of fibroblasts known to play a role in inflammation, because inflammation fosters tumour growth.

Their analysis revealed that the Saa3 gene is responsible for CAFs helping tumour cells to progress. When the researchers eliminated the expression of this gene in the CAFs, these cells behaved like normal fibroblasts, losing the ability to accelerate tumour cell progression. Researchers had managed to "reprogramme" these cells, which had been stripped of their pro-tumour properties.

In human samples of pancreatic cancer, the researchers have identified the same population of pro- tumour fibroblasts, and have observed that when the SAA1 gene (the human version of Saa3) is overexpressed, the prognosis for the patients is far worse.
           haleplushearty.blogspot.com

MicroRNA regulates movements of tumour cells

Cancer cells can reactivate a cellular process that is an essential part of embryonic development. This allows them to leave the primary tumor, penetrate the surrounding tissue and form metastases in peripheral organs.

During an embryo's development, epithelial cells can break away from the cell cluster, modify their cell type-specific properties, and migrate into other regions to form the desired structures. This process is known as an epithelial–mesenchymal transition EMT is reversible and can also proceed in the direction from mesenchymal cells to epithelial cells (MET).

It is repeated multiple times during embryonic development and ultimately paves the way for the formation of organs in the human body. Tumor cells can reactivate the program. Although this is a completely normal process during embryogenesis, it also plays an important role in the spread of tumor cells within the body and in the formation of metastases.

Tumor cells are able to reactivate the EMT/MET program. By doing so, they obtain characteristics of stem cells and develop strong resistance to classical and state-of-the-art targeted cancer therapies. An EMT also makes it easier for cancer cells to break away from the primary tumor, to penetrate into surrounding tissue and into blood vessels, to spread throughout the body and to form metastases in distant organs, which is ultimately responsible for the death of most cancer patients.

Regulation the cellular EMT program prevents the development of malignant tumors and the formation of metastases such as in the case of breast cancer, researchers focused specifically on microRNAs (miRNAs), a class of very short non-coding RNAs with a considerable effect on gene regulation.
          haleplushearty.blogspot.com

Breast milk can kill cancer

Breast milk is being used to fight cancer after scientists discovered it contains a substance that kills tumour cells.

Trials in patients with bladder cancer yielded good results and researchers believe the compound breast milk contains – nicknamed Hamlet – will also help tackle bowel cancer and cervical cancer.

Breast milk is better than chemotherapy because it does not destroy healthy cells. Professor Catharine Svanborg, who made the initial discovery, said ‘There’s something magical about Hamlet’s ability to target tumour cells and kill them.’

Human breast milk contained a protein called alpha-lactalbumin, which is transformed into a cancer-fighting agent when in the gut.

Prof Svanborg, an immunologist at Lund University in Sweden, made the chance discovery that the substance kills tumour cells when working on antibiotics.

New breast milk is a very good source of  antimicrobial agents. During one
experiment we needed human cells and bacteria to be present, and we chose human tumour cells for practical reasons.

‘To our amazement, when we added this compound of milk, the tumour cells died. The substance attacks cancer cells  in numerous ways – first evading the cell’s outer defences, then targeting the ‘power station’ mitochondria and the  nucleus.

These actions cut off the cell’s energy source and ‘programme’ it to commit suicide, in a process called apoptosis.
Early trials in patients with bladder cancer show those injected with Hamlet start shedding dead tumour cells in their urine within days.